Skip to content

DSIP

Tags: DSIP, Sleep, Neuromodulator

Quick Summary

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide researched for improving slow-wave sleep, reducing sleep latency, and modulating stress and pain pathways. Clinical evidence is limited but suggests potential benefits for sleep and recovery.

Overview

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1974 from rabbit brain. Originally identified for sleep-promoting properties, DSIP has since been investigated for broader neuromodulatory effects including stress reduction, pain modulation, and endocrine regulation. Clinical efficacy and mechanisms remain under active research.

Key Benefits

  • Promotes deep (delta) slow-wave sleep
  • Reduces sleep latency and nocturnal awakenings without morning grogginess
  • May reduce stress and cortisol through HPA-axis modulation
  • Potential pain-relief effects in some clinical reports

Mechanism of Action

DSIP appears to modulate multiple neurotransmitter systems (GABA, NMDA, endogenous opioid pathways) and influence the hypothalamic–pituitary–adrenal axis, supporting natural sleep architecture rather than producing sedation.

Molecular Information

  • Type: Nonapeptide
  • Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
  • Length: 9 amino acids
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Research Indications

  • Sleep: deep-sleep enhancement and improved sleep efficiency (Most Effective)
  • Mood: anxiety and mood stabilization (Effective)
  • Chronic pain: reported benefit in small clinical series
  • Stress management and withdrawal support
  • Athletic recovery (short-term protocols)

Research Protocols

Goal Dose Frequency Route
Sleep Enhancement 100–200 mcg Once nightly Subcutaneous
Chronic Pain 250–300 mcg Daily IV or SubQ
Stress Management 150 mcg Evening Subcutaneous
Withdrawal Support 200–300 mcg Twice daily IV preferred
Athletic Recovery 100–150 mcg Post-training Subcutaneous

Timing: Best taken 30–60 minutes before intended bedtime; some prefer earlier evening dosing (2–3 hours) for gradual onset. Consistent timing improves outcomes.

Interactions

Compatible / Complementary

  • Melatonin — Synergistic
  • Selank — Synergistic
  • Epitalon — Synergistic
  • Semax — Compatible
  • Cortisol modulators — Compatible
  • Growth-hormone peptides — Compatible

Monitor

  • GABA agonists — Monitor combination

Avoid

  • Opioid medications — Use caution

How to Reconstitute

  1. Clean vial tops with an alcohol swab and let dry completely.
  2. Always use bacteriostatic water (BAC) and sterile technique.
  3. For a 1 mg vial, add 1 mL BAC water (creates 1 mg/mL or 1000 mcg/mL).
  4. Inject water slowly down the vial wall to minimize foaming.
  5. Gently roll between palms; do not shake.
  6. Solution should be clear and colorless after mixing.
  7. For a 100 mcg dose, draw 0.1 mL (10 units on an insulin syringe).
  8. Store reconstituted peptide in the refrigerator immediately.

Quality Indicators

Positive Signs

  • White to off-white lyophilized powder before reconstitution
  • Clear, colorless solution after proper mixing
  • Short stability window — use reconstituted solution within 14 days
  • Source quality and third‑party testing (COA) are essential due to instability
  • Minimize light and temperature fluctuations to protect the peptide

Warning Signs

  • Yellow or cloudy solution indicates degradation or contamination — discard

What to Expect

  • First dose: noticeable sleep pressure and easier sleep onset
  • Night 1–3: deeper sleep, fewer awakenings, vivid dreams possible
  • Day 2–5: improved morning refreshment and daytime energy
  • Day 5–10: cumulative stress reduction and mood improvements
  • Post-cycle: benefits may persist 1–2 weeks after stopping

Side Effects & Safety

  • Generally well tolerated with minimal side effects in reported series
  • Possible mild drowsiness or dizziness initially
  • Occasional headaches reported in sensitive individuals
  • No tolerance or dependence reported in studies to date
  • Avoid driving until individual response is known
  • Not recommended during pregnancy or breastfeeding

Quick Start

  • Typical dose: 100–200 mcg per injection
  • How often: Once daily, 30–60 minutes before bed
  • Where to inject: Subcutaneous — abdomen, thigh, upper arm
  • Storage: Refrigerate 2–8°C; protect from light; use within 14 days
  • Cycle length: 5–10 consecutive days; 2–4 week break between cycles

References

Chronic Insomnia Double-Blind Study (1991)

  • Human | 15–30 nmol | 6 consecutive nights | Improved sleep efficiency

Double-blind crossover study showed DSIP improved objective sleep quality with higher sleep efficiency and shorter sleep latency versus placebo; subjective improvements were modest.

Chronic Pain Pilot Study (1984)

  • Human | 25 nmol IV | 10 days | 6/7 patients improved

DSIP significantly reduced pain levels in 6 of 7 patients with chronic pain conditions (including migraine and tinnitus) with concurrent mood improvements.

Alcohol and Opioid Withdrawal (1984)

  • Human | Variable doses | 5–10 days | Symptom reduction

Clinical reports indicate DSIP aided withdrawal management by improving sleep and reducing anxiety.